Scott Myers
Chairman bij DYNAVAX TECHNOLOGIES CORPORATION
Vermogen: 218 894 $ op 31-03-2024
Momenteel actieve connecties
| Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
|---|---|---|---|---|
| Julia Eastland | F | 59 |
Rainier Therapeutics, Inc.
 Rainier Therapeutics, Inc. BiotechnologyHealth Technology Rainier Therapeutics, Inc. operates as a biotechnology company that develops a targeted biologic for the potential treatment of metastatic bladder cancer. It provides Vofatamab, an antibody that is focused on the fibroblast growth factor of bladder and other cancer. The company was founded by Stephen Lau and is headquartered in San Leandro, CA. | 14 jaar |
| Ryan Spencer | M | 46 | 19 jaar | |
| Seth Harmon | M | 45 | 1 jaar | |
| Stefan Antonsson | M | - |
Ironshore Therapeutics, Inc.
 Ironshore Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ironshore Therapeutics, Inc. operates as a pharmaceutical company. The firm offers HLD-200, HLD-900, the morning routine and the delexis products. It develops commercialization of a proprietary drug delivery system. The company was founded by David Gordon MacLeod Lickrish in 2008 and is headquartered in Toronto, Canada. | - |
| Stephanie C. Read | F | 48 |
Ironshore Therapeutics, Inc.
Ironshore Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ironshore Therapeutics, Inc. operates as a pharmaceutical company. The firm offers HLD-200, HLD-900, the morning routine and the delexis products. It develops commercialization of a proprietary drug delivery system. The company was founded by David Gordon MacLeod Lickrish in 2008 and is headquartered in Toronto, Canada. | 4 jaar |
| Ildiko Mehes | F | - |
Ironshore Therapeutics, Inc.
Ironshore Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ironshore Therapeutics, Inc. operates as a pharmaceutical company. The firm offers HLD-200, HLD-900, the morning routine and the delexis products. It develops commercialization of a proprietary drug delivery system. The company was founded by David Gordon MacLeod Lickrish in 2008 and is headquartered in Toronto, Canada. | 2 jaar |
| Matthew Bartholomae | M | - | 1 jaar | |
| Neil Bander | M | - |
Convergent Therapeutics, Inc.
 Convergent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Convergent Therapeutics, Inc. is a clinical stage pharmaceutical company located in Cambridge, MA. The company focuses on developing next generation radiopharmaceutical therapies for prostate and other cancers. The company's proprietary technology involves dual-targeted radionuclide therapy (RNT) developed by Dr. Neil Bander, a professor of urologic oncology at Weill Cornell Medicine and licensed to Convergent by Cornell University. The company's lead product candidate, Conv01-?, is a monoclonal antibody conjugated with actinium-225 (225Ac), a radioactive alpha particle emitter, designed to bind to the prostate-specific membrane antigen (PSMA). If FDA-approved, Conv01-? would be the first antibody approved to direct a radioisotope to prostate cancer, and the first drug approved for the use of 225Ac in a cancer treatment. The company was founded by Philip Wayne Kantoff and Neil H. Bander, and Philip Wayne Kantoff has been the CEO since incorporation. | - |
| Andrew Muratore | M | - | 3 jaar | |
| Metin Kurtoglu | M | 46 | 1 jaar | |
| Meg Smith | F | - | 5 jaar | |
| Deborah Baron | F | 55 | 3 jaar | |
| Peter Paradiso | M | 73 | 4 jaar | |
| Brent MacGregor | M | 60 | 4 jaar | |
| Peggy Phillips | F | 70 | 18 jaar | |
| Carsten Brunn | M | 53 | 1 jaar | |
| Francis Cano | M | 79 | 15 jaar | |
| Luke Walker | M | - | 2 jaar | |
| Philip Kantoff | M | 69 |
Convergent Therapeutics, Inc.
Convergent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Convergent Therapeutics, Inc. is a clinical stage pharmaceutical company located in Cambridge, MA. The company focuses on developing next generation radiopharmaceutical therapies for prostate and other cancers. The company's proprietary technology involves dual-targeted radionuclide therapy (RNT) developed by Dr. Neil Bander, a professor of urologic oncology at Weill Cornell Medicine and licensed to Convergent by Cornell University. The company's lead product candidate, Conv01-?, is a monoclonal antibody conjugated with actinium-225 (225Ac), a radioactive alpha particle emitter, designed to bind to the prostate-specific membrane antigen (PSMA). If FDA-approved, Conv01-? would be the first antibody approved to direct a radioisotope to prostate cancer, and the first drug approved for the use of 225Ac in a cancer treatment. The company was founded by Philip Wayne Kantoff and Neil H. Bander, and Philip Wayne Kantoff has been the CEO since incorporation. | - |
| Frank Lanza | M | 62 | 5 jaar | |
| Kevin Bain | M | 66 |
Ironshore Therapeutics, Inc.
Ironshore Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ironshore Therapeutics, Inc. operates as a pharmaceutical company. The firm offers HLD-200, HLD-900, the morning routine and the delexis products. It develops commercialization of a proprietary drug delivery system. The company was founded by David Gordon MacLeod Lickrish in 2008 and is headquartered in Toronto, Canada. | 2 jaar |
| Dan Kisner | M | 77 | 14 jaar | |
| David Novack | M | 62 | 11 jaar | |
| Robert Janssen | M | 70 | 14 jaar | |
| Aniz Girach | M | 57 | 2 jaar | |
| Elaine Sun | F | 53 | 3 jaar | |
| Caroline Andersson | F | - | 9 jaar | |
| Jean-Christophe Tellier | M | 65 | 13 jaar | |
| David Ferguson | M | 72 |
Ironshore Therapeutics, Inc.
Ironshore Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ironshore Therapeutics, Inc. operates as a pharmaceutical company. The firm offers HLD-200, HLD-900, the morning routine and the delexis products. It develops commercialization of a proprietary drug delivery system. The company was founded by David Gordon MacLeod Lickrish in 2008 and is headquartered in Toronto, Canada. | - |
| Alex Oh | M | - | 2 jaar | |
| Patricia Novy | M | - | 3 jaar | |
| James B. Bucher | M | 59 | 1 jaar | |
| Riccardo Manetti | M | - | 4 jaar | |
| Jeff P. Coon | M | 61 | 5 jaar | |
| Sarah Gheuens | M | 45 | 1 jaar | |
| Todd Lopeman | M | - | 10 jaar | |
| John L. Slebir | M | 58 | 3 jaar | |
| Dong Yu | M | - | 3 jaar | |
| Justin Burgess | M | - | 12 jaar | |
| Nicole Arndt | F | - | - |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
| Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
|---|---|---|---|---|
| Jonathan Violin | M | 49 | 3 jaar | |
| Edward Myles | M | 52 | 4 jaar | |
| Christopher Henney | M | 83 | 13 jaar | |
| Arnold Lippa | M | 77 |
DOV Pharmaceutical, Inc.
 DOV Pharmaceutical, Inc. Miscellaneous Commercial ServicesCommercial Services DOV Pharmaceutical, Inc. discovers and develops novel drugs. It focuses on the development of novel product candidates for disorders of the central nervous system, or CNS. It have drug development programs that are at the preclinical, Phase I and Phase II clinical stages, including DOV 21,947 (in a Phase II clinical trial for depression), DOV 102,677 (which has completed a Phase I clinical trial) and a preclinical discovery program in reuptake inhibitors and GABA modulators. The company was founded by Arnold S. Lippa in May, 1995 and is headquartered in Somerset, NJ. | 11 jaar |
| Luke Evnin | M | 60 | 5 jaar | |
| William Heiden | M | 64 | 8 jaar | |
| Jan Skvarka | M | 57 | 2 jaar | |
| Georgia Erbez | F | 57 | 4 jaar | |
| Stephen Lau | M | 52 |
Rainier Therapeutics, Inc.
Rainier Therapeutics, Inc. BiotechnologyHealth Technology Rainier Therapeutics, Inc. operates as a biotechnology company that develops a targeted biologic for the potential treatment of metastatic bladder cancer. It provides Vofatamab, an antibody that is focused on the fibroblast growth factor of bladder and other cancer. The company was founded by Stephen Lau and is headquartered in San Leandro, CA. | - |
| Andrew Hack | M | 50 | 4 jaar | |
| Patrick Baeuerle | M | 66 | 5 jaar | |
| James Parsons | M | 58 | 10 jaar | |
| Robert A. Uger | M | 53 | 8 jaar | |
| Anders Fredrik Williamsson | M | 70 | 7 jaar | |
| Ron Hunt | M | 59 | 7 jaar | |
| Nancy Whiting | M | 51 | - | |
| Robert L. Kirkman | M | 75 | 8 jaar | |
| Gino Santini | M | 66 | 8 jaar | |
| Gerald McMahon | M | 69 | 5 jaar | |
| Thomas Leysen | M | 63 | 3 jaar | |
| Karl Lundström | M | 62 | 2 jaar | |
| Norman J. Ornstein | M | - | - | |
| Helena Tayton-Martin | M | 57 | 4 jaar | |
| Scott A. Beardsley | M | 56 | 4 jaar | |
| Carl-Johan Blomberg | M | 72 | 2 jaar | |
| Anne Phillips | M | 70 | 1 jaar | |
| Henrik Juuel | M | 59 | 5 jaar | |
| Penka Petrova | M | 56 | 8 jaar | |
| Joseph Vittiglio | M | 52 | 5 jaar | |
| Robert Perez | M | 59 | 11 jaar | |
| Kathrine O'Brien | F | 61 | 1 jaar | |
| Bill Silbey | M | 65 | - | |
| David Johnson | M | 41 | 1 jaar | |
| Kristian Humer | M | 49 | 2 jaar | |
| Rosemary Harrison | M | 41 | 1 jaar | |
| Armand de Decker | M | - | - | |
| Jean-Pierre Kinet | M | 70 | - | |
| Nunzio Antonelli | M | - | - | |
| John Fallon | M | 76 | 6 jaar | |
| Thomas Fulton Wilson McKillop | M | 81 | 7 jaar | |
| Maria Christina Schauman | F | 59 | 8 jaar | |
| Mark McDade | M | 69 | 8 jaar | |
| James Sulat | M | 73 | 6 jaar | |
| Barbara H. Deptula | F | 69 | 7 jaar | |
| Michael Kamarck | M | 73 | 1 jaar | |
| Alf Gunnar Martin Nicklasson | M | 69 | 8 jaar | |
| Staffan Lindstrand | M | 62 | 15 jaar | |
| Davey Scoon | M | 78 | 14 jaar | |
| Luke Beshar | M | 65 | 7 jaar | |
| Paolo Pucci | M | 63 | 1 jaar | |
| Albrecht de Graeve | M | 69 | 14 jaar | |
| Linda S. Lennox | F | 59 | 5 jaar | |
| Todd James | M | - | 1 jaar | |
| Paul Walker | M | 49 | 1 jaar | |
| Fabrice Enderlin | M | - | 9 jaar | |
| Thomas Reynolds | M | 65 | 7 jaar | |
| Paul R. Fonteyne | M | 63 | 1 jaar |
Statistieken
| Land | Connecties | % van het totaal |
|---|---|---|
| Verenigde Staten | 54 | 55.67% |
| Canada | 19 | 19.59% |
| België | 11 | 11.34% |
| Zweden | 9 | 9.28% |
| Frankrijk | 1 | 1.03% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Scott Myers
- Persoonlijk netwerk
